CRYOPORT, INC. Earnings Per Share (Basic)
CRYOPORT, INC. (CYRX) reported Earnings Per Share (Basic) of -$0.20 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- CRYOPORT, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.20, a 109.39% decline year-over-year.
- CRYOPORT, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.25.
- CRYOPORT, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.27.
- CRYOPORT, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.18.
- CRYOPORT, INC. earnings per share, basic for fiscal 2025 was $1.40.
- CRYOPORT, INC. earnings per share, basic for fiscal 2024 was -$2.49.
- CRYOPORT, INC. earnings per share, basic for fiscal 2023 was -$2.21.
- CRYOPORT, INC. earnings per share, basic for fiscal 2022 was -$0.93.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.20 10-Q · filed 2026-08-06 | -$0.45 10-Q · filed 2026-08-06 | -$0.73 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.91 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||
| 2026-03-31 | -$0.25 10-Q · filed 2026-05-05 | -$0.52 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$0.70 derived: net income ÷ weighted average shares · filed 2026-05-05 | $1.43 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||
| 2025-12-31 | -$0.27 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$0.45 derived: net income ÷ weighted average shares · filed 2026-03-05 | $1.68 derived: net income ÷ weighted average shares · filed 2026-08-06 | $1.40 10-K · filed 2026-03-05 | ||
| 2025-09-30 | -$0.18 10-Q · filed 2025-11-06 | $1.95 derived: net income ÷ weighted average shares · filed 2026-08-06 | $1.68 10-Q · filed 2025-11-06 | $1.27 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||
| 2025-06-30 | $2.13 10-Q · filed 2026-08-06 | $2.05 10-Q · filed 2025-08-12 | $1.85 10-Q · filed 2026-08-06 | $1.78 10-Q · filed 2025-08-12 | $1.45 derived: net income ÷ weighted average shares · filed 2026-08-06 | $1.43 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.28 10-Q · filed 2026-05-05 | -$0.70 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$2.34 derived: net income ÷ weighted average shares · filed 2026-05-05 | ||
| 2024-12-31 | -$0.42 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$2.06 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$2.49 10-K · filed 2026-03-05 | ||
| 2024-09-30 | -$0.02 10-Q · filed 2025-11-06 | -$1.64 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$2.07 10-Q · filed 2025-11-06 | -$3.38 derived: net income ÷ weighted average shares · filed 2026-03-05 | ||
| 2024-06-30 | -$1.62 10-Q · filed 2025-08-12 | -$2.05 10-Q · filed 2025-08-12 | -$3.37 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$3.68 derived: net income ÷ weighted average shares · filed 2026-03-05 | ||
| 2024-03-31 | -$0.43 10-Q · filed 2025-05-08 | -$1.74 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$2.05 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$2.47 derived: net income ÷ weighted average shares · filed 2026-03-05 | ||
| 2023-12-31 | -$1.31 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.63 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$2.05 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$2.21 10-K · filed 2026-03-05 | ||
| 2023-09-30 | -$0.31 10-Q · filed 2024-11-07 | -$0.73 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$0.89 10-Q · filed 2024-11-07 | -$1.12 derived: net income ÷ weighted average shares · filed 2025-03-07 | ||
| 2023-06-30 | -$0.42 10-Q · filed 2024-08-08 | -$0.58 10-Q · filed 2024-08-08 | -$0.81 derived: net income ÷ weighted average shares · filed 2025-03-07 | -$0.96 derived: net income ÷ weighted average shares · filed 2025-03-07 | ||
| 2023-03-31 | -$0.16 10-Q · filed 2024-05-08 | -$0.39 derived: net income ÷ weighted average shares · filed 2025-03-07 | -$0.54 derived: net income ÷ weighted average shares · filed 2025-03-07 | -$0.77 derived: net income ÷ weighted average shares · filed 2025-03-07 | ||
| 2022-12-31 | -$0.24 10-K · filed 2023-02-28 | -$0.39 derived: net income ÷ weighted average shares · filed 2025-03-07 | -$0.62 derived: net income ÷ weighted average shares · filed 2025-03-07 | -$0.93 10-K · filed 2025-03-07 | ||
| 2022-09-30 | -$0.15 10-Q · filed 2023-11-09 | -$0.38 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$0.69 10-Q · filed 2023-11-09 | -$6.07 derived: net income ÷ weighted average shares · filed 2024-03-13 | ||
| 2022-06-30 | -$0.23 10-Q · filed 2023-08-09 | -$0.54 10-Q · filed 2023-08-09 | -$5.91 derived: net income ÷ weighted average shares · filed 2024-03-13 | -$6.17 derived: net income ÷ weighted average shares · filed 2024-03-13 | ||
| 2022-03-31 | -$0.31 10-Q · filed 2023-05-04 | -$5.68 derived: net income ÷ weighted average shares · filed 2024-03-13 | -$5.96 derived: net income ÷ weighted average shares · filed 2024-03-13 | -$6.19 derived: net income ÷ weighted average shares · filed 2024-03-13 | ||
| 2021-12-31 | -$5.46 10-K · filed 2023-02-28 | -$5.75 derived: net income ÷ weighted average shares · filed 2024-03-13 | -$5.96 derived: net income ÷ weighted average shares · filed 2024-03-13 | -$6.18 10-K · filed 2024-03-13 | ||
| 2021-09-30 | -$0.18 10-K · filed 2023-02-28 | -$0.35 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$0.48 10-Q · filed 2022-11-04 | -$1.72 derived: net income ÷ weighted average shares · filed 2023-02-28 | ||
| 2021-06-30 | -$0.16 10-K · filed 2023-02-28 | -$0.29 10-Q · filed 2022-08-04 | -$1.55 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.86 derived: net income ÷ weighted average shares · filed 2023-02-28 | ||
| 2021-03-31 | -$0.13 10-K · filed 2023-02-28 | -$1.43 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.74 derived: net income ÷ weighted average shares · filed 2023-02-28 | |||
| 2020-12-31 | -$1.32 10-K · filed 2023-02-28 | -$1.66 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.94 10-K · filed 2023-02-28 | |||
| 2020-09-30 | -$0.29 10-K · filed 2023-02-28 | -$0.55 10-Q · filed 2021-11-04 | ||||
| 2020-06-30 | -$0.15 10-K · filed 2023-02-28 | |||||
| 2020-03-31 | -$0.11 10-K · filed 2023-02-28 | |||||
| 2019-12-31 | -$0.55 10-K · filed 2022-02-28 | |||||
| 2013-03-31 | -$0.05 10-K · filed 2013-06-25 | -$169.02 derived: net income ÷ weighted average shares · filed 2014-06-25 | ||||
| 2012-12-31 | -$0.04 10-K · filed 2013-06-25 | |||||
| 2012-09-30 | -$0.04 10-K · filed 2013-06-25 | |||||
| 2012-06-30 | -$0.04 10-K · filed 2013-06-25 | |||||
| 2012-03-31 | -$0.06 10-K · filed 2013-06-25 | |||||
| 2011-12-31 | -$0.07 10-K · filed 2013-06-25 | |||||
| 2011-09-30 | -$0.07 10-K · filed 2013-06-25 | |||||
| 2011-06-30 | -$0.07 10-K · filed 2013-06-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |